<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">

AACR 2024 Poster 5264

KRASG12C Inhibition Synergizes with Checkpoint Blockade in KRASG12C-Mutated Tumor Model

Aaron Li Hua, Jian Feng, Chenpan Nie, Chenfei Zhang, Annie Xiaoyu An, Ludovic Bourre, Jessie JingJing Wang

This poster describes the synergistic effects of Sotorasib with a checkpoint inhibitor on a model harboring the KRASG12C mutation. To evaluate novel therapeutic strategies for treating KRASG12C-mutated tumors, a CT26-KRASG12C tumor model was established using CRISPR/Cas9 and the combination of AMG510 with anti-PD1 therapy was explored by measuring cell proliferation, tumor growth, and immune profiling.

The study presented in this poster compares the two approaches.

Download this Poster to Discover:

  • CRISPR Methods used to generate a CT26 KRAS 12C tumor model
  • Tumor model response to Sotorasib and anti-PD1 combination in comparison to Sotorasib treatment alone
  • Immune profiling of tumors of CT26 KRAS 12C tumor model treated with Sotorasib and checkpoint inhibitor

Download the Poster Now!



Download Now

Your privacy is important to us.
We'll never share your information.